Alexei Kharitonenkov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9669979/publications.pdf

Version: 2024-02-01



ALEYEL KHARITONENKOV

#	Article	IF	CITATIONS
1	FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation, 2005, 115, 1627-1635.	3.9	1,748
2	Fibroblast Growth Factor 21 Corrects Obesity in Mice. Endocrinology, 2008, 149, 6018-6027.	1.4	890
3	The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes. Cell Metabolism, 2013, 18, 333-340.	7.2	752
4	The Metabolic State of Diabetic Monkeys Is Regulated by Fibroblast Growth Factor-21. Endocrinology, 2007, 148, 774-781.	1.4	659
5	Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State. Diabetes, 2010, 59, 2781-2789.	0.3	657
6	An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice. Cell Metabolism, 2013, 17, 790-797.	7.2	443
7	The Circulating Metabolic Regulator FGF21 Is Induced by Prolonged Fasting and PPARα Activation in Man. Cell Metabolism, 2008, 8, 169-174.	7.2	441
8	FGF21 is an Aktâ€regulated myokine. FEBS Letters, 2008, 582, 3805-3810.	1.3	344
9	FGFâ€21/FGFâ€21 receptor interaction and activation is determined by βKlotho. Journal of Cellular Physiology, 2008, 215, 1-7.	2.0	296
10	The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Molecular Metabolism, 2013, 2, 31-37.	3.0	227
11	Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions. Diabetes, 2013, 62, 1453-1463.	0.3	191
12	FGF21 Requires βklotho to Act In Vivo. PLoS ONE, 2012, 7, e49977.	1.1	155
13	Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319. PLoS ONE, 2013, 8, e58575.	1.1	141
14	LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys. PLoS ONE, 2013, 8, e65763.	1.1	139
15	Different roles of N―and C―termini in the functional activity of FGF21. Journal of Cellular Physiology, 2009, 219, 227-234.	2.0	114
16	Fundamentals of FGF19 & amp; FGF21 Action In Vitro and In Vivo. PLoS ONE, 2012, 7, e38438.	1.1	99
17	FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties. Trends in Endocrinology and Metabolism, 2015, 26, 608-617.	3.1	98
18	Genetic disruption of uncoupling protein 1 in mice renders brown adipose tissue a significant source of FGF21 secretion. Molecular Metabolism, 2015, 4, 537-542.	3.0	78

#	Article	IF	CITATIONS
19	Fibroblast activation protein (FAP) as a novel metabolic target. Molecular Metabolism, 2016, 5, 1015-1024.	3.0	56
20	Overexpression of β-Klotho in Adipose Tissue Sensitizes Male Mice to Endogenous FGF21 and Provides Protection From Diet-Induced Obesity. Endocrinology, 2016, 157, 1467-1480.	1.4	55
21	FGF19 and FGF21: In NASH we trust. Molecular Metabolism, 2021, 46, 101152.	3.0	38
22	Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity. Molecular Metabolism, 2018, 13, 45-55.	3.0	36
23	The Nuclear Receptor Rev-erbα Regulates Adipose Tissue-specific FGF21 Signaling. Journal of Biological Chemistry, 2016, 291, 10867-10875.	1.6	29
24	Cholic Acid Supplementation of a High-Fat Obesogenic Diet Suppresses Hepatic Triacylglycerol Accumulation in Mice via a Fibroblast Growth Factor 21–Dependent Mechanism. Journal of Nutrition, 2018, 148, 510-517.	1.3	12
25	Another Kid on the Block: Long-acting FGF21 Analogue to Treat Dyslipidemia and Fatty Liver. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e417-e419.	1.8	4
26	Break on Through to the Other 1. Cell Metabolism, 2014, 20, 554-555.	7.2	3